Drug Profile
Research programme: HIV infections - Aphoenix
Alternative Names: AFX-400 series; HIV infections research programme - AphoenixLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aphoenix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in Japan
- 22 Jun 2005 The AFX-400 series is available for partnering (http://www.aphoenix.com)
- 22 Jun 2005 Preclinical trials in HIV infections treatment in Japan (unspecified route)